LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa.
The commencement of dosing in this group of patients, who have a greater baseline level of visual acuity than those treated before, follows a positive review of the clinical data from the first phase II patient cohort in the study.
Data so far showed that all three of the first cohort of subjects in the study had reported a "rapid and significant improvement in vision".
ReNeuron expects to report further short-term read-outs from the study in mid-2019.
"We remain extremely encouraged by the positive efficacy data we have seen thus far in the Phase I/II study with our hRPC cell therapy candidate in retinitis pigmentosa patients. These results have already attracted considerable interest, particularly from those in the ophthalmology field, and we look forward to reporting further results from the study as it progresses over the coming months," Chief Executive Officer Olav Hellebo said.
ReNeuron shares were trading up 6.4% at 74.49 pence each.
Reneuron (RENE)